Protein Kinase Inhibitors: all 15,278 studies that test it

Page 58 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To TumorsCompletedNCT01105533Phase 1Results posted
• Safety of PCI-32765 in Chronic Lymphocytic LeukemiaCompletedNCT01105247Phase 1/2Results posted
• Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerCompletedNCT01104155Phase 2Results posted
• Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01103323Phase 3Results posted
• Velcade and Sorafenib in Unresected or Metastatic Renal Cell CarcinomaTerminatedNCT01100242Phase 2Results posted
• Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)CompletedNCT01097694Phase 2Results posted
• Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade DysplasiaCompletedNCT01097304Phase 2Results posted
• Dinaciclib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01096342Phase 2Results posted
• A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel RegimenCompletedNCT01094288Phase 1Results posted
• Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous LeukemiaCompletedNCT01093573Phase 1/2Results posted
• Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT01093222Phase 2Results posted
• An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib StudyTerminatedNCT01090414Phase 1/2Results posted
• Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung CancerCompletedNCT01090011Phase 1Results posted
• Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)TerminatedNCT01089595Phase 2Results posted
• MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)TerminatedNCT01085331Phase 1/2Results posted
• AZD6244 (Selumetinib) in Treating Patients With Multiple MyelomaCompletedNCT01085214Phase 2Results posted
• LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or GefitinibCompletedNCT01085136Phase 3Results posted
• Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to ChemotherapyCompletedNCT01083368Phase 1/2Results posted
• Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male VolunteersCompletedNCT01082380Phase 1Results posted
• Gemcitabine and Pazopanib in Metastatic Pancreatic CancerTerminatedNCT01080248Phase 2Results posted
• Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant RecipientsCompletedNCT01079143Phase 3Results posted
• A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)CompletedNCT01077544Phase 1Results posted
• Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaCompletedNCT01076543Phase 1/2Results posted
• A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)TerminatedNCT01076400Phase 1/2Results posted
• An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).CompletedNCT01076010Phase 3Results posted
• Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
• ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedNCT01075048Phase 1/2Results posted
• Understanding Mechanisms of Acquired Resistance to BIBW2992CompletedNCT01074177Not applicableResults posted
• Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212CompletedNCT01072175Phase 2Results posted
• Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1/2Results posted
• Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseTerminatedNCT01068782Phase 2Results posted
• Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal TumorCompletedNCT01068769Phase 2Results posted
• Letrozole and RAD001 With Advanced or Recurrent Endometrial CancerActive, not recruitingNCT01068249Phase 2Results posted
• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaActive, not recruitingNCT01064648Phase 1/2Results posted
• Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT01064479Phase 2Results posted
• Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney CancerCompletedNCT01064310Phase 3Results posted
• Calcineurin Inhibitor Sparing After Kidney TransplantationCompletedNCT01062555Phase 1/2Results posted
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01062425Phase 2Results posted
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT01062399Phase 1/2Results posted
• Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the UterusTerminatedNCT01061606Phase 2Results posted
• Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01061177Phase 4Results posted
• A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With LymphangioleiomyomatosisCompletedNCT01059318Phase 2Results posted
• Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the SkinTerminatedNCT01059305Phase 2Results posted
• Dose Escalation Study of MLN0128 in Participants With Advanced MalignanciesCompletedNCT01058707Phase 1Results posted
• RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal CancerCompletedNCT01058655Phase 1/2Results posted
• RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck CancerTerminatedNCT01057277Phase 1Results posted
• ARQ 197 for Participants With Relapsed or Refractory Germ Cell TumorsTerminatedNCT01055067Phase 2Results posted
• Evaluation of Patients With Bulky GIST Using SunitinibTerminatedNCT01054911Not applicableResults posted
• Phase II Study of RAD001 Head and Neck CancerTerminatedNCT01051791Phase 2Results posted
• Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After DocetaxelCompletedNCT01051570Phase 2Results posted
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
• GW786034 in Patients With Non Small Cell Lung Cancer 3rd LineTerminatedNCT01049776Phase 2Results posted
• Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal SarcomasTerminatedNCT01048723Phase 2Results posted
• RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal CarcinomaCompletedNCT01047293Phase 1/2Results posted
• A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005TerminatedNCT01047007Phase 1Results posted
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesCompletedNCT01045421Phase 1/2Results posted
• Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckCompletedNCT01044433Phase 2Results posted
• Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseCompletedNCT01043874Phase 4Results posted
• Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and CystectomyTerminatedNCT01042795Phase 2Results posted
• Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Phase 3Results posted
• Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTXCompletedNCT01039688Phase 3Results posted
• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia VeraTerminatedNCT01038856Phase 2Results posted
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerCompletedNCT01037790Phase 2Results posted
• Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF InhibitorCompletedNCT01037127Phase 2Results posted
• Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal AdenocarcinomaTerminatedNCT01035658Phase 1/2Results posted
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.CompletedNCT01035229Phase 3Results posted
• Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01034553Phase 1/2Results posted
• CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver CancerCompletedNCT01033240Phase 2Results posted
• Sorafenib With Capecitabine for Patients With Measurable Hepatocellular CarcinomaTerminatedNCT01032850Phase 2Results posted
• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric EpendymomaTerminatedNCT01032070Phase 2Results posted
• Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) PatientsTerminatedNCT01031628Phase 3Results posted
• Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast CancerCompletedNCT01031446Phase 1/2Results posted
• Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube CancerCompletedNCT01031381Phase 2Results posted
• A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01030783Phase 3Results posted
• Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCompletedNCT01030718Phase 1/2Results posted
• A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit MutationCompletedNCT01028222Phase 2Results posted
• Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerCompletedNCT01027598Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
• Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By SurgeryCompletedNCT01026792Phase 2Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerCompletedNCT01026623Phase 1/2Results posted
• Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014CompletedNCT01026402Phase 1Results posted
• Dinaciclib in Treating Patients With Stage III-IV MelanomaTerminatedNCT01026324Phase 1/2Results posted
• Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant RecipientsCompletedNCT01025817Phase 3Results posted
• Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid CancerCompletedNCT01025453Phase 2Results posted
• Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict SensitivityCompletedNCT01024946Phase 2Results posted
• Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.CompletedNCT01024920Phase 2Results posted
• Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial CancerCompletedNCT01023958Phase 2Results posted
• Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.CompletedNCT01023815Phase 3Results posted
• Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.CompletedNCT01022996Phase 2Results posted
• Combination of BI6727 (Volasertib) and BIBF1120 in Solid TumorsCompletedNCT01022853Phase 1Results posted
• A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)CompletedNCT01021748Phase 1Results posted
• Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate CancerTerminatedNCT01020305Phase 1/2Results posted
• Everolimus in de Novo Heart Transplant RecipientsCompletedNCT01017029Phase 4Results posted
• Trial of Gemcitabine With or Without MSC1936369B in Pancreatic CancerCompletedNCT01016483Phase 1/2Results posted
• Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone SarcomaCompletedNCT01016015Phase 2Results posted
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT01015833Phase 3Results posted
• LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian CancerCompletedNCT01015118Phase 3Results posted
• First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsCompletedNCT01014936Phase 1Results posted
• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaCompletedNCT01014351Phase 2Results posted
• Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryCompletedNCT01013649Phase 3Results posted

← Protein Kinase Inhibitors overview